现货，VX-680 (MK-0457, Tozasertib) ，目录号 S1048，CAS号:639089-54-6 HDAC-HSP-Aurora ，Aurora Kinase ，Aurora Kinase YZ剂，Aurora Kinase inhibitors_详细资料

产品信息

英文名： VX-680 (MK-0457, Tozasertib) CAS号： 639089-54-6 保存条件：零下二十度摄氏度低温保存保质期：两年数量：大量供应商：美国Selleck南京办事处规格： 25mg

信号转导通路:  HDAC-HSP-Aurora >> Aurora Kinase >> Aurora Kinase YZ剂 >> VX-680 (MK-0457, Tozasertib)
http://selleck.cn/vx-680-mk-0457-S1048.html
技术数据:

分子量(MW): 464.59

化学式:
C₂₃H₂₈N₈OS

溶解度: DMSO ≥93mg/mL   Water <1mg/mL   Ethanol <1mg/mL

纯度: >99%

稳定性: at -20℃ 2 years

CAS号: 639089-54-6

生物活性

VX-680是小分子Aurora 激酶(AK) YZ剂，作用于Aurora A, Aurora B, 和Aurora C时IC50分别为0.6, 18, 4.6 nM。 ^[1] 虽然VX-680具有多激酶特性，VX-680却诱导相似的细胞毒性，IC50约为300 nM，在G2/M期，核内复制期，及转染ABL或FLT-3激酶的BaF3细胞凋亡时，显示一个Aurora B 类似的YZ表现型。VX-680按时间依赖性YZCAL-62细胞增殖。用VX-680处理14天，明显降低群体的数量和大小，处理8305C下降达到70%，处理CAL-62, 8505C,和BHT-101下降达到90%。用VX-680处理不同ATC细胞，按时间和剂量依赖性YZ细胞增殖，IC50为25到150 nM。在软琼脂中，VX-680明显削弱不同细胞系形成群落的能力。caspase-3的活性分析显示VX-680诱导不同细胞凋亡。VX-680处理CAL-62 细胞12小时，形成DNA含量≥4N细胞累积物。微速摄影分析显示VX-680处理的CAL-62细胞离开细胞中期。VX-680可以YZ组蛋白H3的磷酸化作用。 ^[2]VX-680Z初是由Merk研发的。VX-680二期临床实验已经完成，用于ZL非小细胞肺癌。

参考文献

[1] Mancini M, et al. Br J Haematol. 2012 Jan;156(2):265-8.
[2] Arlot-Bonnemains Y, et al. Endocr Relat Cancer. 2008 Jun;15(2):559-68.
[3] Young MA, et al. Cancer Res. 2006 Jan 15;66(2):1007-14.
[4] Harrington EA, et al. Nat Med. 2004 Mar;10(3):262-7.

客户反馈数据

ENMD-2076 has benn tested it on two different neurobiastoma cell lines(SK-N-BE(2) and CHP-134),being calculated the IC50 by a WST-1(Roche) proliferation assay, as shown in the table below. Its in vitro activity is in the micromolar range and has a comparable effect on both lines.VX-680 was used as standard, and it proved more potent on CHP-134 cells.

SDS-PAGE of CHP-134 cells extracts after 24 h exposure to the indicated drug and concentration. N-myc levels were evaluated and compared to beta actin used as house-keeping protein. Aurora A blockade seems to diminish N-myc expression or stability.

Western blot analysis of Histone and Aurora kinase. 0-10μM MK0457 was added.

B, BLQ1 and UCSF02 cells were treated with increasing concentrations of VX-680 for 48 hours. The percentage of apoptotic cells was determined by fluorescence-activated cell sorting analysis. C, BLQ1 cells were treated with 1 μmol/L VX-680 and cell cycle distribution was determined by flow cytometry at time points of 24 and 48 hours.

VX-680 eliminates Bcr/Abl kinase activities. BLQ1 (T315I mutation) and TXL2 (no mutation) cells were treated with the indicated concentrations of VX-680 with or without 100 nmol/L dasatinib for 24 hours. Western blot analysis was done on total lysates with the antibodies indicated to the left. Blots were stripped and reprobed with Bcr (N-20), Src, and GAPDH antibodies as loading controls.

Responses of human ALL cells to short-term VX-680 treatment. A, BLQ1 cells were treated with 1 μmol/L VX-680 for 3 days. After 3 days, the drug was removed from the medium and cells were cultured without VX-680. During this period (days 3–21) without drug, viability (top left), cell numbers (bottom left), and cell cycle distribution (right) of BLQ1 cells were assessed. B, BLQ1 and BLQ1-VX-Tx cells were cytospun onto glass slides and fixed, dried, and stained with Wright-Giemsa on day 21. All images are at ×63 magnification. C, BLQ1 and BLQ1-VX-Tx cells were treated with 1.5 μmol/L VX-680 or 5 nmol/L vincristine for 72 hours. Cell viability was measured by trypan blue exclusion. *, P < 0.05, vincristine-treated BLQ1 compared with vincristine-treated BLQ1-VX-Tx.

VX-680 and dasatinib synergize to induce cytotoxic activity in wild-type Bcr/Abl-positive human ALL cells. A, TXL2 and UCSF02 cells were exposed to 1 μmol/L VX-680 with or without 100 nmol/L dasatinib for 24 to 72 hours as indicated, after which the percentage of viable cells was determined by trypan blue exclusion. B, TXL2 cells were treated with or without VX-680 and dasatinib for 48 hours in triplicate. **, P < 0.001, VX-680 and dasatinib cotreated TXL2 compared with VX-680–treated or dasatinib alone–treated TXL2 cells. Apoptotic cells were defined by flow cytometry as Annexin V and propidium iodide (PI) double-positive cells. C, TXL2 cells were exposed to VX-680 and/or dasatinib and cell cycle distribution was assessed by flow cytometry.

(G) Nocodazole-arrested HeLa cells were treated with VX-680 and MG132 and stained for CENP-E (Green), pT422 (Red) and DNA (Blue). (H) pT422 fluorescence intensity was normalized to the total CENP-E fluorescence. Plots show the mean of > 15 cells per condition from two independent experiments.

如果需要长期保存，请于零下二十度低温保存。

禁止用于人体及ZL！

特定的存储和包装每个产品的信息在产品说明书上都有注明。大多数Selleck产品，在推荐的条件下存储可稳定保存两年。产品有时建议的储存温度不同，大多数建议储存在-20 ° C ，抗体及蛋白等产品建议-60℃。YZ剂属于化学试剂，可在常温下运输储存两周左右。即使如此，我们保证产品的出货量将保持产品质量的条件下，一般都会放入冰袋。望阁下收到产品后，请按照产品数据表建议适当存储。

退换货政策

1、退换货只针对已付款用户。一张订单Selleck只提供一次退换货服务，为了确保您的权益，请考虑周全后与我们联系。

2、请您确保退换货时，商品、配件、赠品及各种包装完整。

3、因您个人原因造成的商品损坏（如自行使用、分装、受潮、变质、非原物品的等）将不予退换。

4、Selleck目前只支持商品一换一服务，换货时无法加定商品。

5、如您购买商品时Selleck上海办事处已向您提供发票，则办理退货或订单金额发生变更的换货时，请将发票随商品一同返还给Selleck上海办事处赛导通生物科技（南京）有限公司，请您妥善保管发票，如发票丢失，将无法办理退换货。

6、您的订单若办理退换货，运费金额会在您的实际退款中扣除。

温馨提示：不可用于临床ZL。

分子量(MW):	464.59
化学式:	C₂₃H₂₈N₈OS
溶解度:	DMSO ≥93mg/mL Water <1mg/mL Ethanol <1mg/mL
纯度:	>99%
稳定性:	at -20℃ 2 years
CAS号:	639089-54-6

	ENMD-2076 has benn tested it on two different neurobiastoma cell lines(SK-N-BE(2) and CHP-134),being calculated the IC50 by a WST-1(Roche) proliferation assay, as shown in the table below. Its in vitro activity is in the micromolar range and has a comparable effect on both lines.VX-680 was used as standard, and it proved more potent on CHP-134 cells.
	SDS-PAGE of CHP-134 cells extracts after 24 h exposure to the indicated drug and concentration. N-myc levels were evaluated and compared to beta actin used as house-keeping protein. Aurora A blockade seems to diminish N-myc expression or stability.
	Western blot analysis of Histone and Aurora kinase. 0-10μM MK0457 was added.
	B, BLQ1 and UCSF02 cells were treated with increasing concentrations of VX-680 for 48 hours. The percentage of apoptotic cells was determined by fluorescence-activated cell sorting analysis. C, BLQ1 cells were treated with 1 μmol/L VX-680 and cell cycle distribution was determined by flow cytometry at time points of 24 and 48 hours.
	VX-680 eliminates Bcr/Abl kinase activities. BLQ1 (T315I mutation) and TXL2 (no mutation) cells were treated with the indicated concentrations of VX-680 with or without 100 nmol/L dasatinib for 24 hours. Western blot analysis was done on total lysates with the antibodies indicated to the left. Blots were stripped and reprobed with Bcr (N-20), Src, and GAPDH antibodies as loading controls.
	Responses of human ALL cells to short-term VX-680 treatment. A, BLQ1 cells were treated with 1 μmol/L VX-680 for 3 days. After 3 days, the drug was removed from the medium and cells were cultured without VX-680. During this period (days 3–21) without drug, viability (top left), cell numbers (bottom left), and cell cycle distribution (right) of BLQ1 cells were assessed. B, BLQ1 and BLQ1-VX-Tx cells were cytospun onto glass slides and fixed, dried, and stained with Wright-Giemsa on day 21. All images are at ×63 magnification. C, BLQ1 and BLQ1-VX-Tx cells were treated with 1.5 μmol/L VX-680 or 5 nmol/L vincristine for 72 hours. Cell viability was measured by trypan blue exclusion. *, P < 0.05, vincristine-treated BLQ1 compared with vincristine-treated BLQ1-VX-Tx.
	VX-680 and dasatinib synergize to induce cytotoxic activity in wild-type Bcr/Abl-positive human ALL cells. A, TXL2 and UCSF02 cells were exposed to 1 μmol/L VX-680 with or without 100 nmol/L dasatinib for 24 to 72 hours as indicated, after which the percentage of viable cells was determined by trypan blue exclusion. B, TXL2 cells were treated with or without VX-680 and dasatinib for 48 hours in triplicate. **, P < 0.001, VX-680 and dasatinib cotreated TXL2 compared with VX-680–treated or dasatinib alone–treated TXL2 cells. Apoptotic cells were defined by flow cytometry as Annexin V and propidium iodide (PI) double-positive cells. C, TXL2 cells were exposed to VX-680 and/or dasatinib and cell cycle distribution was assessed by flow cytometry.
	(G) Nocodazole-arrested HeLa cells were treated with VX-680 and MG132 and stained for CENP-E (Green), pT422 (Red) and DNA (Blue). (H) pT422 fluorescence intensity was normalized to the total CENP-E fluorescence. Plots show the mean of > 15 cells per condition from two independent experiments.

您可能感兴趣的产品

现货，VX-680 (MK-0457, Tozasertib) ，目录号 S1048，CAS号:639089-54-6 HDAC-HSP-Aurora ，Aurora Kinase ，Aurora Kinase YZ剂，Aurora Kinase inhibitors

产品信息

联系我们

关注我们